Some news items you might have missed: • LGBTQ Nation: Gilead has announced that its new twice-yearly pre-exposure prophylactic (PrEP) injectable medication, lenacapavir, has passed a Phase III clinical trial finding the medication protected patients from HIV in 100% of cases. Continue reading “Twice-Yearly PrEP Med Passes Phase 3 Trial + More News”
Twice-Yearly PrEP Med Passes Phase 3 Trial + More News
